secwatch.observer — SEC 8-K summary
======================================

Issuer:     Akari Therapeutics Plc (AKTX)
CIK:        0001541157
Form:       8-K
Filed at:   2025-09-25T23:59:59+00:00
Accession:  0001493152-25-014962
Event type: debt
Sentiment:  neutral
Materiality: 0.65
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Akari Therapeutics extends April 2023 notes to Aug 2026, closes $500k tranche, reveals PH1 ADC data
--------------------------------------------------------------------------------

- April 2023 notes maturity extended to Aug 31, 2026; conversion/exercise price amended to $0.81/ADS ($0.000405 per ordinary share).
- Paid ~$81,700 accrued interest through Sep 30, 2025; default claims released.
- Closed second tranche of August 2025 Notes: issued $625k principal for $500k; total $3.5M principal issued.
- April 2023 warrants exp. extended to Aug 2030, 342,420 ADSs issuable; Series A warrants exp. extended to Apr 2030 for 4,891,272 ADSs.
- Preclinical data: PH1 ADC suppresses AR-V7 in mCRPC model; plans to present at scientific conference.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1541157/000149315225014962/0001493152-25-014962-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1541157/000149315225014962/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-014962

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer